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Adrenal suppression with intranasal betamethasone drops
M. D. FLYNN, M.D.,* P. BEASLEY, F.R.C.S.,** J. E. TOOKE, D.M.*
Abstract
Intranasal betamethasone sodium phosphate drops (Betnesol) are frequently used to relieve nasal congestion due to polyp-
osis. We report a case of significant hypothalamic-pituitary-adrenal suppression secondary to the long-term use of intran-
asal betamethasone drops. This case emphasizes that the topical application of potent corticosteroids may produce
systemic effects.
Introduction
The absorption of potent corticosteroids through mucosal sur-
faces may result in significant systemic effects. Suppression of
the hypothalamic-pituitary-adrenal axis is a recognized compli-
cation of high dose inhaled corticosteroids used in the treatment
of bronchial asthma (Smith and Hodson, 1983) but is thought to
be uncommon with the use of topical intranasal corticosteroids.
We report for the first time a case of secondary adrenal suppres-
sion related to treatment with intranasal betamethasone sodium
phosphate drops 0.1 per cent (Betnesol).
Case report
A 75-year-old man was admitted as an emergency with a
history of recurrent syncope. He had postural hypotension with a
standing blood pressure of 80/0 mmHg compared with a supine
measurement of 110/80 mmHg. His symptoms could not be
attributed to dehydration, autonomic failure or cardiac dysrhyth-
mia and his clinical presentation was thought to be due to hypo-
adrenalism. He had a history of bronchial asthma and of nasal
polyposis treated with surgery 7,13,17 and 25 years earlier. He
had been using betamethasone 0.1 per cent nasal drops (Bet-
nesol) continuously for a minimum of three years in a prescribed
dosage of one drop to each nostril, four times daily. On direct
questioning he had been more liberal in his application fre-
quently squirting it into his nostrils. He also used a 'Ventide'
inhaler (salbutamol combined with beclomethasone) adminis-
tering a maximum of one puff twice daily (maximum dose of
beclomethasone 100 micrograms daily).
Adrenal insufficiency was confirmed by the measurement of a
9.00 am basal serum cortisol of only 47 nmol/1 (normal
> 150 nmol/1), rising to only 271 nmol/1 (normal >550 nmol/1),
one hour after the administration of 250 micrograms of intra-
venous tetracosactrin (Synacthen) (Clayton, 1989). There was
no evidence of hypopituitarism and primary adrenal insuffi-
ciency (Addison's disease) was excluded by an absence of pig-
mentation, negative adrenal antibodies and normal plasma renin
activity. Plasma adrenocorticotrophic hormone (ACTH) was
only 15 ng/1 in contrast to values >200 ng/1 which would be
expected in primary adrenal failure (Clayton, 1989). Adrenal
stimulation with an intramuscular injection of 1 mg of tetra-
cosactrin (Synacthen Depot), confirmed secondary adrenal sup-
pression with a baseline serum cortisol of 20 nmol/1 rising to
only 228 nmol/1 at four hours but rising to 664 nmol/1 by 24
hours (serum cortisol remains <280 nmol/1 in primary hypo-
adrenalism).
He was treated with intravenous hydrocortisone and sub-
sequently with hydrocortisone 20 mg in the morning and 10 mg
in the evening. His nasal polyps were treated by surgery and his
topical nasal corticosteroids discontinued. Oral corticosteroids
replacement was continued for 14 months until there was evi-
dence of the return of normal function of his hypothalamic-
pituitary-adrenal axis when his 9.00 am cortisol achieved the
normal range after temporary corticosteroid withdrawal.
Discussion
Betamethasone is a potent corticosteroid which, when admin-
istered as nasal drops, has been demonstrated in a double blind
placebo controlled trial to be effective in controlling symptoms
of nasal polyps (Chalton et al., 1985).
Adrenal suppression is reported with the intranasal appli-
cation of dexamethasone (Normal et al., 1967) and with beclo-
methasone in a case with previous multiple surgery and recurrent
sinusitis (Sorkin and Warren, 1986).
There are no specific formal studies of betamethasone absorp-
tion but nasal corticosteroids absorption may be facilitated by an
engorged nasal mucosa and an increase in mucosal surface area
due to nasal polyps. Nasally administered corticosteroids may
also be swallowed and betamethasone is freely absorbed from
the gastrointestinal tract (Reynolds, 1989) without being
destroyed in theliver. The potential for systemic absorption of
betamethasone is illustrated by a reported case of iatrogenic
Cushing's syndrome related to abuse of betamethasone nasal
drops (Stevens, 1988).
A regular dose of oral prednisolone in excess of 7.5 mg will
result in adrenal suppression. The total prescribed dose of intran-
asal betamethasone in this case is estimated as 200 micrograms/
day (Chalton et al., 1985), which is equivalent to less than 3 mg
of prednisolone. It is probable that our patient exceeded the pre-
scribed dosage of intranasal betamethasone on an intermittent
basis, for a prolonged period of time. Adrenal suppression
resulted from both increased nasal and intestinal absorption. His
presentation with adrenal insufficiency may reflect an inadver-
tent reduction in his betamethasone administration or a minor
intercurrent illness precipitating adrenal crisis. Betamethasone
has little mineralocorticoid activity (Reynolds, 1989) which may
have contributed to the presentation with postural hypotension
and syncope. A period of 9-12 months before the recovery of
adrenal function is to be expected (Dixon and Christy, 1980).
Inhaled beclomethasone (as Ventide inhaler) is unlikely to
have contributed significantly to adrenal suppression in this case
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as inhaled doses of 1600 micrograms daily are required to pro-
duce detectable adrenal suppression (Sherman et al., 1982) and
doses of 8000 micrograms if administered intranasally (Harris et
al., 1974).
Adrenal suppression as described here is a gross end product
of the systemic absorption of topical corticosteroids. It is impor-
tant to be aware of more subtle effects such as are being reported
with inhaled corticosteroids which include impaired glucose and
lipid metabolism (Krusynska et al., 1987) and impaired bone
metabolism which may predispose to osteoporosis (Ali et al.,
1991). Unsuspected adrenal suppression may also put the patient
at risk during intercurrent illness and in the peri-operative period
if consideration is not given to appropriate temporary glucocorti-
coid replacement.
This case supports the recent recommendation to limit the use
of intranasal corticosteroids to a one month course used not more
than six times a year (Drug and Therapeutics Bulletin, 1989) and
emphasizes that topical steroids should be prescribed with care.
Consideration should be given to the use of metered dosages and
the use of other corticosteroids such as Budesonide which may
have less systemic absorption and have less systemic bioavail-
ability due to more rapid degraduation and higher first pass clear-
ance (Ryrfeldt et al., 1982, Pedersen and Fugslang, 1988).
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